SDAMLO
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SDAMLO (SDAMLO).
Sdamlo is a combination of amlodipine, a dihydropyridine calcium channel blocker that inhibits calcium ion influx across cardiac and vascular smooth muscle cells, and sodium salt, which is not a standard component; likely a typo for amlodipine alone or amlodipine/valsartan. Assuming amlodipine: inhibits transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle, leading to peripheral vasodilation and reduced afterload.
| Metabolism | Extensively hepatic (approximately 90%) via CYP3A4 isoenzyme |
| Excretion | Primarily renal (80% as unchanged drug and inactive metabolites); 20% biliary/fecal. |
| Half-life | Terminal elimination half-life is 30-50 hours (mean 40 h); allows once-daily dosing with steady state achieved after 7-10 days. |
| Protein binding | 99.9% bound to plasma proteins (primarily albumin and α1-acid glycoprotein). |
| Volume of Distribution | Vd approximately 0.6 L/kg (indicates extensive extravascular distribution into tissues). |
| Bioavailability | Oral bioavailability is 60-80% due to first-pass metabolism. |
| Onset of Action | Oral: 2-3 hours; peak effect at 6-12 hours. |
| Duration of Action | 24 hours (supports once-daily dosing due to long half-life and sustained pharmacodynamic effect). |
Oral: 5-10 mg once daily, may be titrated up to a maximum of 20 mg once daily based on blood pressure response.
| Dosage form | FOR SOLUTION |
| Renal impairment | No adjustment required for GFR ≥30 mL/min. For GFR <30 mL/min, use with caution; initial dose 5 mg once daily; maximum 10 mg once daily. Not studied in dialysis. |
| Liver impairment | Child-Pugh A: No adjustment. Child-Pugh B: Initial dose 5 mg once daily; maximum 10 mg once daily. Child-Pugh C: Avoid use (insufficient data). |
| Pediatric use | Not approved for use in pediatric patients. No established safety and efficacy data. |
| Geriatric use | Initial dose 5 mg once daily; titrate slowly due to increased sensitivity and risk of hypotension. Maximum 10 mg once daily. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for SDAMLO (SDAMLO).
| Breastfeeding | Amlodipine is excreted into human milk in small amounts; estimated relative infant dose is 2.6% of maternal weight-adjusted dose. M/P ratio not reported. Use with caution, monitoring infant for hypotension and adverse effects. |
| Teratogenic Risk | SDAMLO (amlodipine) is classified as FDA Pregnancy Category C. First trimester: animal studies show no teratogenicity at low doses, but fetal toxicity at high doses; human data limited, no increased risk of major malformations. Second/third trimesters: may cause fetal hypotension, decreased placental perfusion, and fetal growth restriction; use only if benefit outweighs risk. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to dihydropyridines","Severe hypotension (systolic BP <90 mmHg)"]
| Precautions | ["Hypotension in patients with severe aortic stenosis","Increased angina and/or myocardial infarction, especially upon initiation or dose titration","Peripheral edema","Hepatic impairment requires dose adjustment"] |
Loading safety data…
| Fetal Monitoring | Maternal: blood pressure, heart rate, edema. Fetal: ultrasound for growth restriction, amniotic fluid index, fetal heart rate monitoring in third trimester. Neonatal: hypotension, hypocalcemia in first few days if used near delivery. |
| Fertility Effects | No known negative impact on human fertility. Animal studies show no effect on fertility. May be used in women of childbearing age without specific fertility concerns. |